Cancer is one of leading killers worldwide. One doctor has innovated genetic treatment to help give hope to those with the most serious types of cancer. That doctor, Dr. Clay Siegall, has shaped his Seattle Genetics to become one of the leading cancer therapy companies in the world.
In a recent interview, Dr. Siegall discussed his innovative approach to cancer treatment. And how his business skills helped make Seattle Genetics one of the premier cancer treatment companies in the country. When asked about the origins of Seattle Genetics, Dr. Siegall mentioned the ordeal one of his family members went through during cancer treatment. After seeing this family member nearly die from the side effects of the treatment, Dr. Siegall sought to find a more effective way to treat cancer patients.
Seattle Genetics was founded in 1998 and for over two decades have helped thousands of patients through the use of targeted gene therapy. When discussing the financial side of the business, Dr. Siegall mentioned that one of the profit centers for the company is the selling of a proprietary drug. The drug was the first antibody-drug conjugate ever approved by the Food and Drug Administration. Additionally, when asked about how long it took for Seattle Genetics to become profitable, Dr. Siegall mentioned that it took about ten years.
When also asked about the challenging times at Seattle Genetics, Dr. Siegall mentioned that there were some moments during the first and the second year of the company that their cash was close to being depleted. However, due to Dr. Siegall’s persistence, as well as the hard work of the research staff, Seattle Genetics was able to survive and grow for the next two decades.
Dr. Clay Siegall was educated at the University of Maryland where he received a Bachelor of Science degree in Zoology. Later, Dr. Siegall would receive a Doctorate in Genetics from George Washington University. Today Dr. Siegall is a leading authority on genetic cancer treatments whose Seattle Genetics is helping innovate the world of cancer therapy.